CLINICAL AND PATHOGENETIC FEATURES OF METABOLIC SYNDROME IN GENERAL DRUG PRACTICE
DOI:
https://doi.org/10.11603/1811-2471.2018.v0.i2.8617Keywords:
metabolic syndrome, obesity, clinical and pathogenetic features.Abstract
Metabolic syndrome today is an urgent medical and social problem in the world, which attracts attention of a wide range of specialists: endocrinologists, cardiologists, gastroenterologists, rheumatologists, gynecologists, urologists, family doctors and pediatricians. Experts of WHO characterize the metabolic syndrome as pandemia of the 21st century. In this work, the analysis of scientific sources of own and foreign scientists, which formed the concept of "metabolic syndrome" is given. The accumulated fundamental knowledge and clinical observations are shown, which give an opportunity to deeply analyze the etiology and clinical pathogenesis, course, progression and consequences of the metabolic syndrome. The urgency of the problem is caused not only by its significant prevalence, but also by the rejuvenation of the disease, the negative impact on quality and life expectancy, a significant increase in the risk of cardiovascular disasters. In Ukraine, mortality from atherogenic cardiovascular diseases is one of the first places in the overall mortality of the population. The presence of a metabolic syndrome increases the risk of developing cardiovascular complications in 3–6 times and is a hard economic burden for health systems in Ukraine and the world. In such conditions, the metabolic syndrome, in the concept of which several factors of high vascular risk are combined at once, can not but attract attention of the specialists. The urgency of the problem is due to the fact that this condition is reversed, that if you pvescribe appropriate treatment, it is possible to achieve disappearance, or at least a decrease in the severity of its main manifestations. A patient with a metabolic syndrome is a patient with multiple associated pathologies, who, along with cardiovascular manifestations, have liver, biliary tract, lipid and carbohydrate metabolism changes, problems with joints and weight. Patients with metabolic syndrome most often are patients of general medical practice, but often, not all components of the syndrome attract attention by masking and further treated unilaterally.
References
Babinets, L.S., Shevchenko, N.O. (2017). Aktualnist vikovoho aspektu klinichnoho perebihu i vedennia khvorykh na khronichnyi pankreatyt [Actuality of the age-related aspect of clinical course and management of patients with chronic pancreatitis]. Zdobutky klinichnoi i eksperymentalnoi medytsyny – Achievements of Clinical and Experimental Medicine, 4, 5-11 [in Ukrainian].
Baydurin, S.A. (2013). Metabolicheskiy sindrom: osobennosti patogeneza, printsipy diagnostiki, profilaktiki i lecheniya [Metabolic syndrome: features of pathogenesis, principles of diagnosis, prevention and treatment]. Meditsina – Medicine, 1, 8-13 [in Russian].
Brodska, A.Iu. (2010). Abdominalno-vistseralne ozhyrinnia yak kliuchova lanka rozvytku metabolichnoho syndromu u zhinok v pre menopauzi [Abdominal-visceral obesity as a key link in the development of metabolic syndrome in premenopausal women]. Pryrodnychyi almanakh – Natural Almanac, 14, 25-31 [in Ukrainian].
Butrova, S.A. (2001). Metabolicheskiy sindrom: patogenez, klinika, diagnostika, podkhody k lecheniyu [Metabolic syndrome: pathogenesis, clinic, diagnosis, approaches to treatment]. Russkiy meditsinskiy zhurnal – Russian Medical Journal, 2, 56-60 [in Russian].
Ginzburg, M.M. (2000). Ozhirenie i metabolicheskiy sindrom. Vliyanie na sostoyanie zdorovya, profilaktika i lechenie [Ozhirenie i metabolicheskiy sindrom. Vliyanie na sostoyanie zdorovya, profilaktika i lechenie]. Samara: Parus [in Russian].
Dontsov, A.V. (2013). Svyaz abdominalnogo ozhireniya s metabolicheskimi i gormonalnymi narusheniyami u bolnykh IBS [The connection of abdominal obesity with metabolic and hormonal disorders in patients with IHD]. Nauchnye vedomosti – Seriya Meditsina. Farmatsiya – Scientific Bulletin – Series Medicine. Pharmacy, 11, 80-83 [in Russian].
Zaiats, M.M., & Zimenkovskyi, A.B. (2013). Kliniko-ekonomichnyi analiz yak skladova optymizatsii farmakoterapii metabolichnoho syndromu [Clinical and economic analysis as a component of optimization of pharmacotherapy of metabolic syndrome]. Zaporozhskiy meditsynskiy zhurnal – Zaporizhzhia Medical Journal, 4, 10-12 [in Ukrainian].
Zorii, I.A., Biletskyi, S.V., Shevchuk, N.M., & Kretsu, T.M. (2007). Kliniko-biokhimichni markery metabolichnoho syndromu v ditei ta pidlitkiv [Clinical and biochemical markers of metabolic syndrome in children and adolescents]. Bukovynskyi medychnyi visnyk – Bukovyna Medical Bulletin, 2, 40-44[in Ukrainian].
Kovalenko, V.M., Talaieva, T.V., & Kozliuk, A.S. (2013). Metabolichnyi syndrom: mekhanizmy rozvytku, znachennia yak faktora sertsevo-sudynnoho ryzyku, pryntsypy diahnostyky ta likuvannia [Metabolic syndrome: mechanisms of development, significance as a factor of cardiovascular risk, principles of diagnosis and treatment]. Ukrainskyi kardiolohichnyi zhurnal – Ukrainian Cardiological Journal, 5, 80-87 [in Ukrainian].
Kogay, M.A., Lutov, Yu.V., Pingasov, B.B., Selyatitskaya, V.G., Shorin, Yu.P. (2008). Metabolicheskiy sindrom u lits raznogo pola s izbytochnoy massoy tela i ozhireniem [Metabolic syndrome in persons of different sex with excessive body weight and obesity]. Vestnik novykh meditsinskikh tekhnologiy – Bulletin of New Medical Technologists, 1, 141-143 [in Russian].
Korylchuk, N.I. (2007). Kompleksnyi pidkhid do korektsii hiperinsulinemii, hiperleptynemii ta insulinorezystentnosti v khvorykh z abdominalnym typom ozhyrinnia [Comprehensive approach to the correction of hyperinsulinemia, hyperleptinemia and insulin resistance in patients with abdominal type of obesity]. Visnyk naukovykh doslidzhen – Bulletin of Scientific Researches, 4, 44-46 [in Ukrainian].
Liashhuk R.P., & Liashhuk P.M. (2017). Metabolichnyi syndrom yak mizhdystsyplinarna problema [Metabolic syndrome as an interdisciplinary problem.]. Mizhnarodnyi endokrynolohichnyi zhurnal – International Endocrinology Journal, 7, 499-502 [in Ukrainian].
Krasiuk, O.A. (2008). Metabolichnyi syndrom v praktytsi klinitsysta [Metabolic syndrome in the practice of a clinician]. Viiskova medytsyna Ukrainy – Military Medicine of Ukraine, 4, 105-110 [in Ukrainian].
Martyniuk, H.V., Skoreiko, N.T., Skoreiko, R.S., & Skoreiko, S.Ch. (2016). Metabolichnyi syndrom – deiaki osoblyvosti patohenezu ta yoho vplyv na rozvytok arterialnoi hipertenzii [Metabolic syndrome – some features of pathogenesis and its influence on the development of arterial hypertension]. Bukovynskyi medychnyi visnyk – Bukovyna Medical Bulletin, 2, 85-87 [in Ukrainian].
Melnik, A.A. (2017). Metabolicheskiy sindrom i risk khronicheskoy bolezni pochek [Metabolic syndrome and the risk of chronic kidney disease]. Pochki – Kidneys, 2, 80-90 [in Russian].
Stroev, Yu.I., Tsoy, M.V., Churilov, L.P., & Shishkin, A.N. (2007). Klassicheskie i sovremennye predstavleniya o metabolicheskom sindrome [Classical and modern notions about metabolic syndrome]. Vestnik Sankt-Petersburgskogo universiteta – Bulletin of Saint-Petersburg University, 3-13 [in Russian].
Uchamprina, V.A., Romancova, T.I., Kalashnikova, M.F. (2012). Metabolicheskij sindrom: argumenty “za” i “protiv” [Metabolic syndrome: arguments "for" and "against"]. Ozhirenie i metabolizm – Obesity and Metabolism, 2, 17-27 [in Russian].
CHumakova, G.A., Veselovskaya, N.G., Gricenko, O.V., Ott, A.V. (2014). Metabolicheskij sindrom: slozhnye i nereshennye problemy [Metabolic syndrome: complex and unresolved problems]. Rossiyskiy kardiologicheskiy zhurnal – The Russian Cardiology Journal, 3, 63-71 [in Russian].
Alexander, C.M., Landsman, P.B., Teutsch, S.M., & Haffner, S.M. (2003). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 52,1210-1214.
Cefalu, W.T. Cannon, Ch.P. (2007). Insulin resistance and cardiometabolic risk. Atlas of Cardiometabolic Risk, 27-37.
Day, C. (2005). Diagnostic definitions – metabolic syndrome. Br. J. Diab. Vasc. Dis., 5, 115-118.
Despres, J.P., & Brewer, H.B. (2008). Metabolic syndrome: The dysmetabolic state of dysfunctional adipose tissue and insulin resisyance. Eur. Heart J., 10, 1–3.
Fan, J.G., Zhu, J., & Li, X.J. (2005). Fatti liver and the metabolic syndrome among Shanghai adults. J. Gastroenterol. Hepatol., 12, 1825-1832.
Ferrannini, E., Sironi, A.M., Iozzo, P., & Gastaldelli, A. (2008). Intraabdominal adiposity, abdominal obesity, and cardiometabolic risk. Eur. Heart J., 10, 4-10.
Ford, E.S. (2005). Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of evidence. Diabetes Care., 28, 1769-1778.
Grundy, S.M., Brewer, H.B. Jr., & Cleeman, J.I. (2004). Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute. American Heart Association conference on scientific issues related to definition Circulation, 109 (3), 433-438.
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) The Metabolic syndrome: time for a critical appraisal. Diabetes Care, 28, 2289-2304.
Matfin, G. (2007). Challenges in developing therapies for the metabolic syndrome. Br. J. Diabetes Vasc. Dis., 4, 152-156.
Panchal, S.K., Poudyal, H., & Brown, L. (2012). Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J. Nutr., 142 (6), 1026-1032.
Reaven, G.M. (1988). Banting lecture: Role of insulin resistance in human disease. Diabetes, 37, 1595-1607.
Reaven, G.M. (2004). Insulin resistance, cardiovascular disease, and the metabolic syndrome. Diabetes. Care, 27, 1011-1012.
Reaven, G.M. (2003). Insulin resistance/compensatory hyperinsulineamia, essential hypertension, and cardiovascular disease. J. Clin. Endocrinol. Metabol., 88, (6), 2399-2403.
Shea, S., Aymong, E., & Zybert, P. (2003). Obesity, fasting plasma insulin, and C-reactive protein levels in healthy children. Obes. Res., 11, 95-103.
